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CHAPTER ONE

REVIEW OF THE LITERATURE

1.1 Cystic Fibrosis
Cystic Fibrosis (CF) was first described by Dorothy Andersen in 1938 in order to distinguish
the disease from others such as celiac disease (Davis, 2006). While both of these diseases
have very similar symptoms such as malnutrition and gastrointestinal (GI) tract problems, CF
differs by also causing mucus accumulation and lung infections. CF is a disease that affects
how ions are transported in epithelial cells. The areas of the body affected by this disease
include the lungs, gastrointestinal tract, pancreas, sweat glands and reproductive system.
When chloride ions (Cl-) are not being transported correctly, patients produce very thick
mucus in their airways which eventually causes lung infections. Because of this the most
common cause of death is obstructive lung disease which is present in approximately 90% of
patients (Cutting, 2010) CF also affects the intestines, pancreas resulting in constipation,
diarrhea and malnutrition. Currently, CF affects approximately 1 in every 2500 Caucasian
people (Liu et. al., 2017) (Akabas, 2000). The average age of survival for this disease is
approximately 40 years old and is continuing to rise due to more direct and personalized
medicines. Because there is currently no cure for this disease and the many different DNA
mutations that can cause CF, research is focused on the treatment of symptoms and
understanding the genetics of the mutations themselves.
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1.2 Epithelial Cells
Ion transport in epithelial cells is where CF has the largest effect in the body.
Epithelial cells contain a basolateral (adjacent to the interstitial fluid) and apical (adjacent to
the lumen) side and are located in regions of the body that produce mucus such as the lungs,
GI tract and pancreas. The apical side of these cells is where the CFTR (Cystic Fibrosis
Transmembrane Conductance Regulator) protein is located. These epithelial cells also
usually form as a monolayer, so the junctions between the cells are very important. These
cell junctions are termed as: tight, adherens, desmosomes, hemidesmosomes, and gap
junctions. Epithelial cells normally function as a barrier for airways to protect the body from
pathogens and allow for transport of ions and H2O. However, when the CFTR protein is
mutated, the epithelial cells cannot function normally, so ions are released and absorbed in
the wrong concentrations, so airways become much drier. This results in thicker mucus and
more lung infections (De Rose et. al., 2018). CF affects mostly epithelial cells which
function in transporting chloride and bicarbonate. When the gene that encodes CFTR is
mutated, these epithelial cells experience a drastic decrease in ion transport which, in turn,
creates the symptoms commonly associated with CF.

1.3 CFTR Gene
CF was determined to be an autosomal recessive disease by Andersen and Hodges in
1946 (Andersen et. al., 1946) (Davis, 2006) (Stolzenburg et. al., 2017). Forty decades later,
the gene associated with encoding the CFTR protein was identified by a collaboration of 3
papers by Kerem et. al. 1989, Riordan et. al. 1989 and Rommens et. al., 1989. These papers
show that in order to have the disease, one must inherit two recessive alleles for the CFTR
gene. A person who is a carrier for the disease will contain one allele that encodes a dominant
allele and one that encodes a recessive allele. The CFTR gene is located on the Q (long) arm
of chromosome 7, is approximately 190 kb (kilobases), contains 27 exons and the mRNA is
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composed of 6128 nucleotides. Because the CFTR gene is much larger than most other genes,
this also leads to a larger number of DNA variation. There are approximately 352 DNA
mutations that are associated with causing CF located on this gene (O’Neal and Knowles,
2018) (Tsui and Dorfman, 2013).
Because there are so many different types of mutations associated with the CFTR
gene and CFTR protein, these have been categorized into 5 classes based on how the mutation
affects the CFTR protein. The 5 classes are described in Table 1.1. For example, the ΔF508
mutation is a Class 2 mutation because it results in a misfolded CFTR protein. The CFTR
gene ultimately encodes the CFTR protein; however, there are many other factors involved
in how this gene is expressed and regulated.
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Table 1.1 Classes of CFTR Protein Mutations. This table describes the 5 classes of CFTR
mutations and how each mutation affects the CFTR protein (Condren et. al., 2013).
Class

Functionality of Mutation

Example Mutation

1

Translation of CFTR is Interrupted

G542X

2

Misfolded CFTR

ΔF508

3

Defective CFTR Gate

G551D

4

Defective Conductivity of CFTR Gate

R117H

5

Decreased Amount of CFTR
Expression

3849 + 10Kb C
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1.4 Gene Regulation
The CFTR promoter’s regulatory elements were described in 1991 by Chou et. al.
In this paper, the group identifies regions of the promoter that are regulatory by using a
bacterial chloramphenicol acetyltransferase (CAT) reporter assay as well as incorporating
various regions of the promoter from 0 to 3600 base pairs. By analyzing each section
separately, the group was able to see the regulatory regions as the amount of CAT activity
changes. If the level of CAT was higher for 0-20bp, and lower for 0-89bp, then there was
likely a repressive transcription factor or other gene regulation factor somewhere between
20 and 89 base pairs. With these results, the group provided several descriptions of the
promoter. The region from -226 to +98 base pairs was found to be enough of the promoter
to provide tissue specificity. By transfecting this into several different types of cells and
measuring the CAT activity, it was obvious that this promoter was specific for the Caco2
cell line and not other non-epithelial cell lines. The region from -273 to 190 was found to be
GC rich and may be associated with Sp1 (associated with RNA polymerase). Deletion of the
GC rich area at 273 was shown to decrease CAT activity. Other regions were also shown to
decrease CAT activity: -345 to -277, -297 to -291 and -604 to -596. These also contained
similar sequences to known inhibitor sequences in rat collagen genes and etc. The results of
this paper indicate that there are regions in the CFTR promoter that can affect gene
regulation and therefore the severity of the CF disease (Chou et. al., 1991)
Gene regulation takes place in order to control how much of a protein is produced
as well as when. In the simplest case, DNA is transcribed into RNA which is then translated
into a protein. However, most genes have regulatory factors which further control these
processes. This involves a very complex system of regulatory machinery such as transcription
factors, enhancers and epigenetics.
Transcription factors (TF) are regulatory proteins that influence the transcription of genes.
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This regulation is because most TFs have a specific “binding motif” or DNA sequence that it
can bind to in the genome. Once the TF binds to its DNA motif, the TF can either repress or
activate transcription, and/or recruit other proteins to that location to regulate transcription.
This allows genes to be turned on or off based on certain situations that are occuring in the
cell (Lambert et. al., 2018). Based on this, one can predict if a variant will increase or decrease
transcription based on the TFs that are associated with that region.
Enhancers are often associated with transcription factors because enhancers can also
be bound by TFs. When a TF binds to an enhancer region, the gene associated will be
transcriptionally activated much more than it would be normally which means that there will
be more of the protein encoded by this gene in the cell. This is helpful for cells to turn on
genes when that protein is needed in certain cells.
Chromatin also has a large role in gene regulation. Chromatin aides in allowing the DNA in
cells to be packaged more efficiently. Chromatin is composed of nucleosomes which are
composed of an octamer (8 domains) of histone proteins. This is useful because each histone
can be wrapped with approximately 150 base pairs of DNA. Considering the human genome
is composed of three billion base pairs, this is essential for each cell to be able to contain the
entirety of the genome. Without this mechanism, DNA strands would have to be much shorter
and less sophisticated or cells would need to be larger (Mendenhall and Bernstein, 2008).
Chromatin and histones are also often modified depending on the type of cell. The
most well studied modifications include acetylation, phosphorylation and methylation.
Acetylation involves adding an Acetyl group to the amino acid Lysine which is bound to the
histone. The N terminus acts as a tail where most acetylation can occur. Once this is done,
the N terminus of the histone is no longer able to interact with the negatively charged
phosphate groups of the DNA. This is due to the Lysine losing its positive charge when it is
acetylated. Phosphorylation involves the addition of a phosphate group to one of three amino
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acids: serine, threonine and/or tyrosine. This works by either inducing other proteins to bind
or not allowing histones to be able to stay bound to the DNA. DNA methylation also interacts
with the N terminus tails that are accessible when DNA is bound to histones. Methylation
occurs at Lysine or Arginine on Histone 3 or Histone 4 by histone methyltransferases (HMTs)
and may activate or repress transcription. (Kouzarides, 2007) (Mendenhall and Bernstein,
2008). Chromatin and histone modifications are one way of regulating gene expression. These
can also serve to identify promoter and enhancer regions which also have a role in gene
expression.
In the human genome, 99% of the DNA sequence is shared among everyone. This
99% is composed of regions that have been selected for over time due to evolution to
protect from disease. For example, a variant in this region could be fatal; therefore, this
variant will not be passed down to future generations. It is also composed of areas that do
not code for a protein and therefore are important for gene regulation.
In this project, conserved regions can tell us more about how the promoter SNPs
affect gene expression. If they are in a highly conserved region, this may mean that the
variant is rare and causes the CF disease to be more severe because it disrupts the sequence
that has been evolutionarily “selected for”. On the other hand, if a variant is in a nonconserved region, the variant may not result in severe CF. This is because the variant does
not disrupt the “selected for” sequence.
Most mutations that cause CF are found in the coding region of the CFTR gene; however,
mutations in the noncoding regions such as enhancer regions, chromatin and promoter region
may also lead to CF. The mutations can affect anywhere from one base that doesn’t change
the amino acid to several bases which affect the entire peptide (chain of amino acids). The
most common mutation is called a Single Nucleotide Polymorphism (SNP). These are so
called because the mutation changes only one nucleotide. These can affect the amino acid or
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it may still code for the same amino acid depending on the codon (3 nucleotides). This is
because several different codons can code for the same amino acid. If the amino acid is not
changed, this is called a silent mutation. If the amino acid is changed it is called a missense
mutation. However, if the amino acid is changed and results in becoming a stop codon, it is
termed a nonsense mutation because the peptide’s translation is stopped prematurely. These
changes to the CFTR gene, whether it is misregulation or mutation, will ultimately affect the
CFTR protein.
1.5 CFTR Protein
The CFTR protein is encoded by the CFTR gene and functions in transporting
Chloride and bicarbonate ions out of the cell. The CFTR protein is in the ABC (ATP Binding
Cassette) Membrane Transporter Family and contains 5 domains that control how it
functions. These domains include: NBD1 (non-binding domain 1), NBD2, TMD1
(Transmembrane Domain 1), TMD2 and R (regulatory) which can be seen in Figure 1.1
(Akabas, 2000) (Corradi et. al., 2015). The structure of the CFTR protein was determined in
2017 using cryomicroscopy (sample is frozen to -150 °C). The newfound structure; however,
does not contain bound ATP molecules and is dephosphorylated. This means that this
structure is only true for a certain state that CFTR is in (Liu et. al., 2017) (Rosser et. al., 2008).
The CFTR protein has structural and amino acid sequence similarity to other ATP binding
proteins as well as proteins that transport ions into or out of the cell. This shows that the
domains of CFTR are crucial for its function.
The R domain is located in the middle of the CFTR protein and is responsible for
opening the CFTR channel. Interestingly, this domain is not found in any other member of
the ABC Membrane Transporter family (Hoffmann et. al., 2018). To open the CFTR ion
channel, the R domain must be phosphorylated. This phosphorylation event occurs on the
serines that are located in the R domain (Ma et. Al., 1997). The 2 NBD domains are located
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on either side of the R domain and are controlled by ATP hydrolysis. Once the R domain is
phosphorylated, the NBD1 and NBD2 can hydrolyze ATP and control the transport of Cl -.
The NBD1 functions by controlling the rate in which the CFTR channel opens whereas the
NBD2 functions by controlling how long the channel stays open (Ma et. al., 1997).
The TMD1 and TMD2 domains are also sometimes referred to as MSDs (Membrane
Spanning Domains) and are the only part of the CFTR protein that is located in the cell
membrane. These domains transverse the membrane with 6 helices each and are responsible
for creating and controlling the chloride/bicarbonate channel. The 2 domains form a
pore/channel and the amino acid content controls the specificity (Rosser et. al., 2008).
The way these domains fold may also explain some of the characteristics of the CFTR
protein. The TMD1, TMD2, R and NBD1 domains have been shown to fold cotranslationally
(while the mRNA is still being transcribed) while the other domains of the protein are folded
once translation has ended (Rosser et. al., 2008). Because the CFTR protein only functions
correctly when all of the domains are working together, a mutation in any one of the domains
will affect the entire CFTR protein.
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Extracellular
TMD1

TMD2

Intracellular
NBD2

NBD1

R

ClFigure 1.1 Structure of the CFTR Protein. The 5 domains of CFTR are shown in
relation to the cell membrane. ATP molecules are shown bound by the NBDs. The
yellow cylinder indicates the channel that Cl- and HCO3 - travel through.
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1.6 DeltaF508 Mutation
The most common DNA mutation associated with CF is the ΔF508 mutation. This
mutation is present in approximately 70% of CF patients and involves an absence of 3
nucleotides. Figure 1.2 shows the location of this mutation in red in relation to the NBD1
domain of the CFTR protein. The nomenclature (ΔF508) describes that there is a change to
the phenylalanine (F) amino acid at the 508 position. In this case, the three nucleotides at this
position would normally code for Phenylalanine; however, with the deletion, the amino acid
Phenylalanine is not added to the protein during translation. This deletion, however, does not
create a frameshift mutation and all other amino acids in the chain are produced in the correct
order. This mutation causes the protein to fold incorrectly and is degraded before proper
placement in the cell membrane. The CFTR protein is degraded by the Endoplasmic
Reticulum Quality Control System. The incorrect folding affects how the TMD1 and TMD2
communicate, therefore, patients with this mutation do not have functional CFTR proteins
(Rosser et. al., 2008) (Serohijos et. al., 2008) (Stolzenburg et. al., 2017). The ΔF508 mutation
is common among many CF patients; however, the severity of CF between patients of the
same genotype is usually not as similar.

1.7 Genotype and Phenotype
In most genetically inherited diseases, the genotype leads to a fairly predictable
phenotype. Genotype is defined as the genetic content that one gets from their parents while
phenotype is the physical characteristics that are caused by the genotype. In CF, however, the
genotype and phenotype are not as predictable. For example, many patients who are born
with the exact same genotype (in this case, certain DNA mutations such as ΔF508), have
drastically different phenotypes as the disease progresses. Figure 1.3 shows this in relation to
sweat chloride levels. Each person in the graph has the same genotype; however, the sweat
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chloride levels are very different (Collaco, 2016). This could be due to several possible
reasons. Most commonly proposed is DNA variation at other genes that influence ion or water
transport (modifier genes), CFTR function, immune responses, etc. or environmental factors.
Modifier genes are genetic factors that affect the progression of the disease, yet do
not code for the disease causing protein. In the case of CF, the CFTR gene contains mutations
that are known to cause CF; however, there are also other genes that code for other channels
or proteins and are shown to influence how the disease presents. Because CF is a monogenic
disease, modifier genes are especially important. In CF, patients who have identical mutations
in the CFTR gene often have differences in lung function, intestinal blockages as well as
diabetes. Therefore, this suggests that there are other areas in the genome regulating the
penetrance of the disease. Several twin studies have shown that when genetics and
environment are controlled, measurements in sweat chloride or FEV1 (Forced Expiratory
Volume in 1 second) are still very different. Another reason modifier genes are suspected to
be regulating severity of the CF disease is because of animal studies. In the ferret and other
species, the presence of Meconium ileus is >75% in CF models, while humans are only
recorded to experience meconium ileus 15% in newborn CF patients which suggests that there
are factors helping to offset some of the symptoms of CF (Cutting, 2011).
Another possible explanation could be that each patient was exposed to different
environmental factors and/or treatments. The environment hypothesis has been further
solidified by the fact that each new treatment is able to raise the life expectancy of CF patients.
If this were not the case, the environment would not be playing a role in the disease severity
(Cutting, 2010). Additionally, individuals are known to have varying amounts of CFTR
protein in their cells
The question this thesis aims to answer is whether certain DNA SNPs found in the CFTR
promoter affect gene regulation with the hope that we can correlate DNA SNPs to either
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severity of the disease, or identify additional DNA SNPs which putatively cause CFTR to be
expressed at disease causing levels.
For example, if the amount of CFTR expression is low, is the severity of CF
symptoms also decreased? If this is proven to be correct, then the treatment for CF could
become even more personalized and effective for patients in the future (Stolzenburg, 2017).
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Figure 1.2 DeltaF508 Mutation. The ΔF508 mutation is shown here in red. This
mutation is the most common in CF patients and is located in the NBD1 domain of
the CFTR protein. The wildtype(wt) NBD1 domain is shown in blue while the
deltaF508 NBD1 is shown in green. S, beta sheets; H, alpha helices (Serohijos et.
al., 2008).
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Figure 1.3 CFTR Severity. This graph shows 822 CF patients who are homozygous
for the DeltaF508 mutation. However, the sweat chloride levels for the patients is
not the same. This indicates that there is another reason for the difference in CF
symptom severity (Collaco, 2016).
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1.8 Reporter Assays
In order to quantify the amount of gene expression, there are several methods:
RNAseq, reporter assays, RT-PCR, etc. RNASeq and RT-PCR quantify gene expression by
measuring mRNA “reads” while reporter assays measure the amount of “reporter” protein
produced. In this project, reporter assays were chosen because these are relatively
inexpensive and produce quick results. These assays use a “reporter”, in this case luciferase,
to mimic the amount of expression a variant causes. The way the reporter assays work is
depicted in Figure 1.5. The SNP of interest is cloned into a plasmid along with the luciferase
gene. The reporter plasmid is then transformed into cells. Once the plasmid is introduced to
the cells, luciferin is added to activate the luciferase enzyme. This reaction creates a specific
amount of light for each SNP which allows for quantification of gene expression. Using this
method, one can predict that the level of luciferase that a single variant causes will correlate
to the amount of CFTR expression that same SNP has in vivo.
This procedure was previously used for hemoglobin genes by Chan et. al., 2012
using DsRed and EGFP in a Dual Luciferase Reporter assay. The plasmids made by this
group included the Beta-globin promoter with the Gℽ, Aℽ and 𝛃globin genes removed. These
locations instead were changed by homologous recombination to the following reporter
genes: DsRed for the Gℽ and Aℽ genes and EGFP for the 𝛃globin gene. The resulting constructs
were assayed by flow cytometry to select cells for the expression analysis. The results of this
study were that most of the assayed cells expressed DsRed while EGFP was not significantly
expressed. This was also replicated in several cell lines which shows that the constructs
contained the regulatory regions that are required for tissue specificity.
1.9 Promoter SNPs
There are approximately 352 DNA mutations associated with CF. Of these mutations,
there are 35 mutations associated with the promoter region of the CFTR gene (CFTR2). This
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region is located upstream of the start codon of the CFTR gene which can be seen in Figure
1.4 (Tsui et. al., 2013). The promoter SNPs in this region may influence gene expression of
the CFTR gene. Many research papers focus on the CFTR gene itself; however, recently more
research has been focused on the promoter region and the respective expression certain SNPs
have on the gene.
In 2013, a paper published by Giordano et. al. described the CFTR promoter area and
how it related to the clinical severity observed in CF patients. This paper focused on the 5’
region of the gene which included approximately 6000 base pairs (bp) upstream of the TSS
(transcription start site). In doing this, the researchers aimed to focus on how the gene was
regulated and how certain mutations affected the level of CFTR protein produced. Several
patients were sequenced, and 17 mutations were narrowed down to test. These 17 mutations
were introduced into 4 cell lines (HepG2, HeLa, PanC-1, and A549) with differing levels of
CFTR protein expression. Each mutation was observed to produce a different amount of
reporter plasmid protein. Of the 17 mutations, 8 were shown to have a significant change in
luciferase expression. The expression of these variants in A549 cells proved to have a 7-18%
difference in luciferase expression than wild type A549 cells. The 8 chosen DNA mutations
all came from very different severities of the CF disease, so this shows that the expression of
CFTR could be explained by variants in the noncoding promoter region (Giordano et. al.,
2013).
By first narrowing down the DNA mutations to this promoter region, one can be
more certain that the mutations will play a role in the regulation of the CFTR gene rather than
causing a misfolded protein or other defect. These results can then be used to identify whether
or not the clinical observations of severity are regulated by the different DNA mutations in
the promoter region of the CFTR gene.

17

A

Promoter

CF gene

B

Figure 1.4 CFTR Promoter Region. The promoter region is located upstream from
the CFTR gene as can be seen in (A). The promoter region of the CF gene contains
many SNPs (B). Each line represents a SNP at that location. Green represents a
synonymous mutation. Red represents a nonsynonymous mutation. Blue and Black
represent a noncoding region.
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Figure 1.5 Reporter Assay Mechanism. The promoter variant of interest is cloned into a
plasmid in front of a “reporter” gene. This will produce an amount of “reporter” that can be
measured. In this case, the luciferase enzyme is produced. Luciferase interacts with
luciferin to produce light (fluorescence) which can be measured.
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1.10 Diagnosis
Because CF is caused by many different DNA variants (of which some are not yet
known), doctors have discovered ways to diagnose CF without conducting a genetic test.
Newborns are screened for the Immunoreactive Trypsinogen (IRT) enzyme, while adults can
be tested using sweat chloride tests or genetic testing. Using the IRT Newborn Test, the doctor
can test the amount of IRT enzyme that is present in the newborn. If the IRT level is raised
approximately 5 percent, then this is a good indicator that the newborn may have CF.
However, further testing is necessary to prove that the patient has CF (Wallis, 1997).
Newborns may also present with Meconium ileus which is a bowel blockage in the first bowel
movement. Meconium ileus is mainly observed in patients who contain Class 1, 2 and 3
mutations. Because this blockage occurs in approximately 20% of CF patients, meconium
ileus is an indicator of CF before any other diagnostic tests can be conducted (Sathe and
Houwen, 2017).
Another way to diagnose patients with CF is to conduct a sweat chloride test. This
is a test that was first introduced in 1959 which determines the amount of salt (chloride) in
the sweat. If the levels are abnormal, this indicates that the patient may have CF (Wallis,
1997). Based on the threshold from the United States Cystic Fibrosis Foundation, a chloride
level of greater than 60 mmol/L is indicative of CF, while a chloride level of 40-59 mmol/L
shows a smaller risk of CF (Gokdemir et. al., 2018).
Genetic testing is the most effective test because patients will often know the exact
mutation that is involved in causing the disease. Knowing this makes the treatment much
more personalized and effective. Without knowing the specific mutation that the patient has,
only the symptoms of the disease can be treated. While each of these diagnostic tests are
effective at determining whether patients have CF, the tests are often used in conjunction to
ensure that patients are not misdiagnosed and that proposed treatments will be effective.
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1.11 Current Treatments
While there is currently no cure for CF, there are several treatments that target the
symptoms of CF. These treatments include: pancreatic enzymes, vitamins, chest physical
therapy (percussive vest) and antibiotics. These treatments are useful because most CF
patients cannot produce pancreatic enzymes, rid their airways of mucus or fight off infections
(Davis, 2006). There are also several drugs available that target specific DNA mutations of
CF, such as the most common ΔF508 mutation. These drugs include: Kalydeco, Orkambi,
Symdeko and Trikafta. Kalydeco is composed of Ivacaftor which is a drug that targets a
mutation related to CFTR rather than its symptoms. This specific drug, ivacaftor, aids in
correcting the gating function of CFTR when it is mutated by the G551D mutation which
means that the Glycine at position 551 has been changed to an Aspartate. This mutation works
by allowing CFTR to be transported to the cell membrane; however, once there its gating
function is defective. It is available for patients 6 years old or older with the G551D mutation
(Condren et. al., 2013). Other drugs are needed for other mutations such as ΔF508 where the
protein does not get transported to the membrane. Orkambi is composed of
Lumacaftor and Ivacaftor and it targets the ΔF508 mutation. This drug functions by allowing
the protein to be transported to the cell membrane instead of being degraded. Once the protein
is transported, the ivacaftor repairs the gating issue from the misfolded protein (Molinski et.
al., 2017). Symdeko is composed of Tezacaftor and Ivacaftor. This drug works by using
Tezacaftor to transport the ineffective CFTR protein to the cell membrane. Then the Ivacaftor
portion aides in opening the gate of CFTR. Trikafta is a triple combination drug that combines
elexacaftor, tezacaftor and ivacaftor to treat specific mutations. Elexacaftor is a CFTR
corrector that binds to a different location than tezacaftor. Both of these correctors work
together to aid the CFTR protein to bypass degradation in the ER and allow the protein to
reach the cell surface. Trikafta is designed to be able to treat over 90% of patients with Cystic
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Fibrosis (Middleton et. al., 2019). While most CF research focuses on CFTR gene mutations
or modifier genes, this thesis aims to describe the relationship between DNA promoter SNPs
and CFTR expression. This hypothesis will be tested using luciferase reporter assays to
quantify the amount of luciferase expression. The results of which will then be used to suggest
how these SNPs may affect expression of the CFTR gene in
patients.
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CHAPTER TWO

METHODS

2.1 Collection of SNPs

DNA Conservation
To begin to narrow down which Promoter SNPs to test, DNA conservation
was studied in several species such as mouse, monkey, dog and elephant.
Conservation was determined using the GERP track on UCSC Genome Browser.
This was then narrowed down to 4 sections of highest conservation within the 3kb
promoter area.
Transcription Factor Motifs
To predict how certain areas of the CFTR promoter could affect gene
expression, transcription factors were also analyzed using the Factorbook and
Encode3 tracks on UCSC Genome Browser. These show regions that are bound by
TFs using Chip-Seq. To study TF binding motifs further, each SNP selected was
entered into CisBP(Catalog of Inferred Sequence Binding Preferences). To find the
TF binding motifs, 10 bases upstream and downstream of each SNP was analyzed.
The reference and experimental SNP were entered into the program which produced
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TFs that were bound to the reference sequence, experimental sequence or both.
Using this, we could predict how gene expression might change based on the TFs
that were bound (Weiraunch et. al., 2014).
SNP Databases
To test the hypothesis, CFTR Promoter SNPs were obtained from 3 sources:
CFTR2, dbSNP and previous data from JLMS Thesis (James Lawlor’s Masters
Thesis) (2017). CFTR2 is a database that lists SNPs found in CF patients and their
family members. Along with the SNP, CFTR2 also describes the symptoms that the
patient or family member has. dbSNP along with Gnomad is a tool used to look at
genes. In this case, dbSNP was used to identify SNPs that are common in the
population which have a >= 0.01 minor allele frequency. In contrast, rare SNPs
have a < 0.01 allele frequency. (Sherry et. al., 2001). The JLMS thesis also provided
several SNPs produced by a Delta SVM (Support Vector Machine) that was used to
determine promoter SNPs that may influence gene expression. This was completed
using reference sequences that were previously described to affect gene expression
along with random sequences to “teach” the SVM. The SVM was then able to
produce scores for each sequence in order to determine which sequences may
influence gene expression. Collecting Promoter SNPs from 3 different databases
provided a dataset that was indicative of SNPs found in CF patients.
Nomenclature
The nomenclature used to identify these SNPs derived from the location of
the variant in relation to the start codon of the CFTR gene as well as the mutation
that is observed. Therefore -887G>T signifies that this variant is 887 base pairs
upstream of the start codon (where the A of the ATG is +1), the major allele is G
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and the minor allele is T. In total, there were 21 SNPs from CFTR2, 5 SNPs from
dbSNP and 8 SNPs from the JLMS thesis.
2.2 G block and Primer Design
G block Design
Synthetic DNA sequences were designed by selecting 3000 base pairs
upstream of the CFTR start codon. The “reference” sequence contained the
reference sequence from UCSC Genome Browser, while the “experimental”
sequence contained the reference sequence with all of the DNA SNPs. These two
sets of sequences were ordered from IDT as G blocks.
Primer Design
To amplify the SNPs from the G block, primers were designed using
Primer3(Table 2.1). These primers contained a specific primer for each SNP as well
as overhangs for Gibson Assembly into the pGL4.23 plasmid. The overhangs were
added to the 5’ end of these primers and were 15 base pairs long. The ideal design
for the primers was to include 60 basepairs upstream and 60 basepairs downstream
of each SNP, including primers. If the SNPs were too close for this design, the 2nd
SNP was included in the primer for the 1st SNP. This worked because the only
difference in the reference and experimental sequences was the SNP in question.
These primers were ordered from
IDT.
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Table 2.1 Primers for Promoter SNPs. Primers were designed for each DNA variant
using Primer3. Shown here are the forward and reverse primers for each SNP. The
lowercase portion is the primer for PCR amplification while the capitalized portion
is the overlap needed for Gibson Assembly. All sequences are 5’ to 3’.
SNP

Forward Primer (5>3)

Reverse Primer (5>3)

-330T>G

gctagcctcgaggatGCTGGGCGGTAAGGACAC

cgccgaggccagatcttgatGCTCCTTCCTCCTCTCCTC

-777T>A

gctagcctcgaggatCCACCCTTGGAGTTCACTCAC

cgccgaggccagatcttgatTAGCGCTTCCTTTGCGTGTC

-1115G>C gctagcctcgaggatTGCCCCTCAGAGAGTTGAAG

cgccgaggccagatcttgatCCTAGTCTCAGTCAGCAAAACA

-1379A>G gctagcctcgaggatGGTTCTTGTCTTTCCATCATGA cgccgaggccagatcttgatGGCCTGATTACTTTATTGCCGA
A
-1801G>A gctagcctcgaggatGGCCACACTAACAGTTATAAAC cgccgaggccagatcttgatACCTGTGTTTTCATCTCTCCAT
C
-1666T>C gctagcctcgaggatCACAGGTAGAGGATTTCAAAC
A

cgccgaggccagatcttgatTTTGAATAGTAGAGAAAAGAGCA

-2321G>C gctagcctcgaggatAAAAGTATGTAACTCCAGTG

cgccgaggccagatcttgatTCACATTAGTTTCATGAAAT

-2990A>G gctagcctcgaggatGGTTTAAATCCCAGTTTCCTCT cgccgaggccagatcttgatAATCTTTACAACACCTTCATG
-3014T>C gctagcctcgaggatGGGGAAGTATGTGAAGTATGT
GT

cgccgaggccagatcttgatCATGTTTTCCCAAGCAAGTT

-2620A>G gctagcctcgaggatGGCCCATTAATCTCTTTCCTGT

cgccgaggccagatcttgatTTCAGGATTTGCATCTAGGTACA

-2386C>T gctagcctcgaggatGGTCTTCCTATGTACATGTGTG cgccgaggccagatcttgatGGAAAGCAGAAATCTACAAACCA
-966T>G

gctagcctcgaggatGGTGGATTAGTCAAGATGTT

cgccgaggccagatcttgatTTGTCTATCCTTTTTAGCCC

-887C>T

gctagcctcgaggatCATCCTGGGCCGGTAATTAC

cgccgaggccagatcttgatCAGGTTTAGGTGAGTGAACT

-8G>C

gctagcctcgaggatGGGAATTGGAAGCAAATGAC

cgccgaggccagatcttgatGGTCTCTGGGGCGCTGGGGT

-26G>A

gctagcctcgaggatGGGAATTGGAAGCAAATGAC

cgccgaggccagatcttgatGGTCTCTCGGGCGCTGGGGT

-34C>T

gctagcctcgaggatGGGAATTGGAAGCAAATGAC

cgccgaggccagatcttgatGGTCCCTGCTAGGGCCGT

-85C>G

gctagcctcgaggatGGGTGGTGTGCGGAGTAG

cgccgaggccagatcttgatAGCTCCTAATGCCAAAGACC

-165G>A

gctagcctcgaggatCACTCGGCTTTTAACCTGGG

cgccgaggccagatcttgatTTTCTCTGACCTGCTGTGATG

-226G>T

gctagcctcgaggatGGGGTGCGTAGTGGGTGGAG

cgccgaggccagatcttgatCGCACACCACCCCTTCCTTT

-274C>A

gctagcctcgaggatGAATCGGGAAAGGGAGGTG

cgccgaggccagatcttgatGGCCCCAAATTTGCTCTAG

-410G>C

gctagcctcgaggatGTCGCCCACCTGCGGGATG

cgccgaggccagatcttgatTCTCCTCCTTCGCTC

-427C>T

gctagcctcgaggatCTGGACCTAAAGAGAGGCCGC cgccgaggccagatcttgatccttACCGCCCAGCACCAGGCCCAT
G ACTGT
C

-444G>A

gctagcctcgaggatCTTCTGTCCTCCAGCGTTGCCA cgccgaggccagatcttgatCAGGCCCATCCCGCAGGTGGGCG
A CTGGACCTAA
ACAG

-461A>G

gctagcctcgaggatGCCGGTGGCTTCTTCTGTCC

cgccgaggccagatcttgatTGGGCGACAGTCGCGGCCTCTC

-484T>G

gctagcctcgaggatGGGAGCCGGTTCTCCCGCCGG

cgccgaggccagatcttgatCTCTCTTTAGGTCCAGTTGGC

-495C>T

gctagcctcgaggatAGGCAGGCTCCGGGGAAGCTG cgccgaggccagatcttgatGCTGGAGGACAGAAGAAGCC
G

-593A>G

gctagcctcgaggatACGTAACAGGAACCCGACTA

cgccgaggccagatcttgatTTCCTAGACCCTCCTTCGC

-721G>A

gctagcctcgaggatAAATGCATCAGACCCACACT

cgccgaggccagatcttgatTAGTCGGGTTCCTGTTACGT

-737G>A

gctagcctcgaggatGCAAAGGAAGCGCTAAGGTA

cgccgaggccagatcttgatGCCTTAGAGAGCCGAAAAGTTCC
GC GG

-751A>G

gctagcctcgaggatCCTGAAACTAATAAAGCTTGGT
T CTTTTCTCCG
cgccgaggccagatcttgatCGCGGCAGTGTGGGTCTGATG

-812T>G

gctagcctcgaggatACGCAAAGCATTATCTCCTCT

-943A>G

gctagcctcgaggatCGCTAAAACACTCCAAAGCCTT cgccgaggccagatcttgatCTGCAAGGAGGTAAGAGGAGATA
C CTTAA
AT GC
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cgccgaggccagatcttgatACCAAGCTTTATTAGTTTCAGGT

2.3 Reporter Plasmid Construct Preparation

PCR (Polymerase Chain Reaction)

To amplify the SNP sequences, PCR amplification of each SNP sequence
was completed using OneTaq Polymerase (NEB). The thermocycler settings were as
follows:
Step

Temperature

Time

Initial Denaturation

94°C

30 seconds

Denaturation

94°C

30 seconds

Annealing

58°C

60 seconds

Extension

68°C

1 minute

Final Extension

68°C

5 minutes

Hold

4°C

∞

(Modified from NEB PCR protocol)
Gel Electrophoresis
To verify that the PCR amplification was successful, a 1.5% agarose gel was
used to show that each SNP size was the expected length (~120 base pairs).
PCR/DNA Cleanup
To isolate the DNA after PCR amplification, a PCR/DNA cleanup kit was
used (NEB). The PCR and DNA cleanup kit allows for up to 5𝜇g of DNA to be
isolated. This kit was used to isolate the DNA from the PCR reaction solutions
(OneTaq Polymerase, dNTPs, buffers, etc.) in order to be used in Gibson Assembly.
The purification works by adding binding buffer to the PCR reaction product and
then adding this to a column. DNA stays bound to the column while several wash
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buffers are added to wash the column of any waste. An elution buffer is then used to
elute the DNA off the column.

Gibson Assembly
Gibson Assembly was used to join the PCR amplified SNP and the pGL4.23
plasmid (Figure 2.1). The Hifi Gibson Assembly kit was used for this reaction
(NEB). The reaction was performed using a thermocycler at 50°C for 60 minutes.
The Gibson
Assembly reaction works by using a nuclease that cuts back the 5’ end of each piece
of DNA. To join 2 pieces of DNA together, overhangs are used on one sequence
that align with the other. In this case, overhangs were added to the primer that was
used to amplify the SNP region from the G block. This overhang matched with the
pGL4.23 plasmid used for the reporter construct. The pGL4.23 was then cleaved at
the EcoRV site to allow the overhangs to align. The overhangs of the plasmid and
the insert (SNP DNA) then ligate together and DNA polymerase fills in the gaps.
The resulting size of the product (Insert + Plasmid) was ~4400 base pairs which
contained the SNP sequence at the EcoRV site of the pGL4.23 plasmid (Gibson et.
al., 2009).
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Figure 2.1 Gibson Assembly Mechanism. Gibson Assembly utilizes overlaps to join
2 pieces of DNA together. Shown here, the insert SNP DNA (yellow) and the
plasmid DNA (blue) have overlaps (black box) on the 5’ ends. The Gibson
Assembly reaction cuts back the 5’ ends, which allows the overlaps to join together.
DNA polymerase fills in any gaps and DNA ligase ligates strands together.
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Transformation
NEB 5 alpha cells were transformed with the Gibson Assembly products
using the heat shock method (42°C for 30 seconds). The cells were supplemented
with SOC media and diluted 1:100 with LB broth before plating on LB + Carb
plates.
Colony PCR
Colony PCR was used to verify that the Gibson Assembly and
Transformation steps were successful before sending for sequencing. One colony
from the transformation step was used along with a forward primer on the insert and
the same reverse primer that was used to PCR amplify the SNP sequence. By using
a primer that was located on the insert and another located on the plasmid, this
would verify that Gibson Assembly and transformation were successful. If
successful, a gel would show a band at the expected size (60-120 base pairs). If the
insert was not present, there would not be a band.
Miniprep
Monarch Miniprep kit was used to isolate the plasmid DNA after
transformation (NEB). This reaction works by lysing the bacteria to release the
plasmid, neutralizing the lysed bacteria to prevent DNA damage and then adding
this solution to a column. Once the solution is added to the column, the plasmid
DNA is bound to the column. The column is then washed with several buffers and
an elution buffer is added to release the DNA. The isolated DNA can be used for
future steps.
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Sequence Verification
To verify that the plasmid contained the correct sequence, the sample was sent to
Eurofins Genomics for sequencing. Miniprepped DNA was sequence verified by
Eurofins Genomics before continuing to nucleofection. The primer used was RV3
which is located on the pGL4.23 plasmid. This primer binds 93 base pairs upstream
of the EcoRV cut site and the location of the insert. Sequencing results were
verified by aligning the reference and experimental constructs with the expected
construct to determine if there were any mutations. Once both sequences were
verified, nucleofections of the plasmids into the 16HBE cells could begin.

2.4 Transfection

Cell Culture
16HBE14o- cells were a kind gift from the Ann Harris lab (Case Western).
The cells were grown in Minimum Essential Medium (MEM), 10% Fetal Bovine
Serum (FBS) and 1% Penicillin/Streptomycin. 16HBE14o- cells were grown at 37
°C/5% CO2. Media was replaced every 2-3 days and cells were passaged with
Trypsin-EDTA before reaching 100% confluency as needed.
Transfections
To test the expression difference between the reference and experimental
SNPs, the reporter constructs were transfected into 16HBE14o- (immortalized
human bronchial epithelial) cells. Transfections were performed using Nucleofector
4D (Lonza). Briefly 100,000 cells per experimental condition were washed with
HBSS and spun down and resuspended in a 1:10 ratio of CFTR reporter Luciferase
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plasmid with a Renilla luciferase (500ng of SNP reporter plasmid, 50ng of Renilla)
to act as a transfection control. The pGL3 vector from Promega served as the
positive control for this experiment because it over-expresses luciferase using the
SV40 Promoter. The pGL4.23 empty vector from Lonza served as the negative
control.
After nucleofection the cells were allowed to recover in the cuvette for ten
minutes, then were split equally into 3 wells of a 12 well plate as technical
replicates and grown according to conditions described above. After nucleofection,
cells were incubated for 48 hours.
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2.5 Luciferase Reporter Assay
The Luciferase Reporter assay was performed using the Dual Luciferase Reporter
Assay System from (Promega) (Figure 2.2). After nucleofection, cells were lysed with
PLB (Passive Lysis Buffer) and rocked for 15 minutes. The lysate was then used for the
remaining steps. A plate reader measured the luciferase and renilla activity in relative
luciferase units (RLU). Each reaction was tested first for Luciferase activity by adding
100 ul LARII then for Renilla activity using 100 ul Stop & Glo Reagent. Renilla
luciferase was used to normalize the readings, therefore each reading is a ratio of
Renilla:Firefly luciferase RLU. Each reaction/well was read and recorded 2 times. The
average of these 2 readings was used for the analysis.

2.6 Data Analysis
To analyze the data after the luciferase assay, the RLU data was compared
between the reference and experimental SNPs. The data collected was composed of
2 readings for Luciferase and 2 readings of Renilla for the 3 replicates of each SNP.
The average of the 3 replicates was taken for both the Renilla and Luciferase
readings and then the Renilla:Luciferase ratio was calculated to normalize the data.
This RLU ratio was then used for the remainder of the data analysis.
To see the difference in gene expression between the reference and
experimental SNPs, T tests were performed to determine if the gene expression
differences were scientifically significant. Further analysis into DNA conservation
and TF association were also analyzed for the SNPs that disrupted gene expression.
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Figure 2.2 Dual Luciferase Protocol. Post-nucleofection, cells were lysed with PLB
and assayed using the Dual Luciferase Protocol. Reagents LARII and Stop&Glo
were added to the cell lysate to activate the firefly luciferase and renilla luciferase
respectively. RLU was measured for Renilla and Firefly luciferase for each reaction
(Promega).
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CHAPTER THREE

RESULTS

Overview
Cystic Fibrosis patients who have the same genotype for the CFTR gene,
sometimes experience varying severities of the disease, which could be due to
differences in CFTR gene expression. Therefore, the hypothesis is that DNA
promoter SNPs influence CFTR gene expression which results in a difference in
disease severity. This theory was tested by isolating CFTR Promoter SNPs,
designing reporter luciferase assays and analysis of SNPs that significantly affected
gene expression. .

3.1 Isolation of SNPs
To begin to collect SNPs, DNA conservation of the CFTR promoter was
noted using the GERP track on UCSC Genome Browser. The 4 regions of DNA
sequence conservation can be seen in Figure 3.1. Conservation of DNA sequences is
often associated with regulatory regions of the genome; therefore SNPs in these
areas could affect gene expression.
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To further narrow down the SNPs to test, TF binding motifs were examined.
Using the ENCODE3 and Factorbook data on UCSC Genome Browser, TF binding
locations were identified for several TFs in the CFTR promoter (Figure 3.1) For
each SNP that was selected, TF motifs were also identified using CisBP. This
program produced a list of TFs that were associated with the reference,
experimental or both sequences. The results of this test can be seen in Figure 3.3.
By identifying TF binding motifs, SNPs could be identified that disrupted gene
expression (Weiraunch et. al., 2014.
In order to test the hypothesis, the next step was to isolate promoter SNPs.
These SNPs were collected from 3 sources: CFTR2, dbSNP and JLMS thesis. From
these sources, a total of 32 SNPs were collected. The distribution of these can be
seen in Figure 3.2. The SNPs from these sources were selected based on several
criteria: location from start codon of the CFTR gene, TF association, conservation
of DNA, symptom severity and allele frequency in the population. These results can
be seen in the following Tables 3.1, 3.2 and 3.3. Collecting SNPs from these
datasets created a higher probability that the
SNPs tested are influencing gene expression and are found in CF patients.
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Figure 3.1 Characteristics of the CFTR Promoter. (A) DNA conservation is shown
here as black bars. These represent the areas of highest DNA conservation. (B)
SNPs are shown here as triangles along the 3kb region of the CFTR promoter. (C)
Gray boxes indicate regions where TF’s were bound using Factorbook and
ENCODE3 data. RNA polymerase is shown where transcription of the CFTR gene
begins.
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Figure 3.2 Promoter SNPs Collection. SNPs were collected from 3 sources: CFTR2,
dbSNP and JLMS Thesis. This chart shows the number of SNPs from each source,
totaling 32 promoter SNPs.
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Table 3.1 JMLS Thesis Predictions and TF association. Data shown here are the
chosen SNPs from JLMS work using a DeltaSVM model to score DNA SNPs. Each
variant was also categorized as promoting or disrupting based on the DeltaSVM
score: promoting meaning that the probability of this SNP being located into a TF
binding location was higher and disrupting meaning that the SNP disrupted a TF
binding location.

SNP

Gene Expression
Transcription Factors
Prediction
330T>G
Increasing
RBBP5, PHF8 , IKZ52, TAF1, IKZF1,
MCM2
777T>A
Increasing
TBP, RBBP5, RNF2

1115G>C

Increasing

YY1, TBP, RBBP5

1379A>G

Increasing

none

1801G>A

Increasing

FOXA1

1666T>C

Increasing

FOXA1

2321G>C

Decreasing

none

2990A>G

Decreasing

none
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Table 3.2 SNPs Found in CF Patients and Family Members on the CFTR2
Database. This table shows the clinical data available for the SNPs collected from
CFTR2. Modified from the CFTR2 database. (A1AT: Alpha 1 antitrypsin; CBVAD:
Congenital absence of the vas deferens)
SNP

Description
-8G>C

Found in 1 CF and 7 non CF chromosomes

-26G>A

Found in 1 out of 1500 control chromosomes in an Italian population

-34C>T

1/50 Chromosomes in children with Disseminated Bronchiectasis, negative sweat
test

-85C>G

Found in CF patient in France, also has 3532AC>GTA mutation + deltaF508

-165G>A

Found in 1 CF chromosome, also has 125G>C in exon 1

-226G>T

CF patient from South Africa, no other mutation detected

-274C>A

Found in a patient with A1AT deficiency

-410G>C

Canadian CF patient, also has deltaF508

-427C>T

Found in a CF patient with A1AT deficiency

-444G>A

No information

-461A>G

CF patient, had meconium ileus, and deltaF508 mutation on the opposite allele

-484T>G

No information

-495C>T

Found in CF patient, the mutation on the other allele is not known

-593A>G

Found in one healthy child

-721G>A

No information

-737G>A

Patient with CBAVD, also has -737G>A and 1001+11C>T mutations

-751A>G

CBVAD patient, also has 869+11C>T (1001+11C>T) mutation

-812T>G

1/50 Non DeltaF508 CF alleles, contains deltaF508 on other allele, pancreatic
insufficiency, cirrhosis

-887C>T

Found in 1/50 CF (Non DeltaF508), moderate pulmonary issues

-943A>G

Found in a patient with A1AT deficiency

-966T>G

No information
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Table 3.3 Common SNPs in the Population. This table shows the SNPs selected
from dbSNP data. These SNPs each have a minor allele frequency of >= 0.01. The
populations shown to have this SNP are also listed.

SNP

Minor Allele Frequency

Population Affected

3014T>C

0.01637

African, Latino

2620A>G

0.01058

African, Latino, European

2386C>T

0.01657

African, Latino, European

966T>G

0.2238

African, Latino, European, East
Asian, European (nonFinnish),
Ashkenazi Jew, South Asian

887C>T

0.01637

African, Latino, European
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Motif Motif
Present in
Both

Motif
Motif Present in
Experimental
Only

Motif Present in
Reference Only

Motif Not
Motif Not
Present

CFTR Gene

Figure 3.3 TF Association Data. Shown here are the predictions from CisBP for TF
association. TFs are indicated on the Y axis while the SNP is located on the X axis
shown in relation to the TSS (arrow). Black squares indicate that the TF motif was
not changed, red squares indicate that the TF motif was only predicted in the
experimental SNP, and blue indicated that the TF motif was only predicted in the
reference SNP. 10 base pairs upstream and downstream of each SNP was used for
analysis.
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3.2 Design of Luciferase Reporter Constructs and Data
To assay the SNPs that were chosen, G blocks, primers and luciferase
reporter constructs were created. G blocks were designed that contained 3000 base
pairs upstream of the start codon for the CFTR gene. The reference G block
contained 3000 basepairs of the reference genome while the experimental G block
contained the reference genome with the 32 mutations. Primers were then created to
amplify specific regions of the G blocks (approximately 120 base pairs total, 60
upstream and downstream of the SNP).
The final design can be seen in Figure 3.4. This design included primers that
contained 16-20 basepairs for the PCR amplification (short black lines) and 16-20
basepairs that served as an overhang for Gibson Assembly (short blue lines). These
primers were 100% successful for PCR amplification from the G block.
To create the Luciferase constructs, the SNP sequence and the plasmid
pGL4.23 were joined using Gibson Assembly. The pGL4.23 plasmid was cleaved at
the EcoRV site which is complementary to the overhang on the SNP sequence. The
two fragments were added to the Gibson Assembly reaction which resulted in a
pGL4.23 + SNP plasmid. Gibson Assembly was 75% successful overall and 59%
successful as pairs of SNPs.
To measure the gene expression change between the reference and
experimental SNP constructs, nucleofection into 16HBE cells and luciferase
reporter assays were conducted. Nucleofections were performed using 16HBE cells.
These express high levels of CFTR and contain the same machinery (regulatory
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elements) as the cells affected by CF. The reporter constructs (reference or
experimental) and Renilla plasmid were transfected into each reaction. Once
transfected, the cells were incubated for 2 days and then lysed with PLB. This lysate
was then used for the luciferase reporter assay.
To quantify the amount of luciferase produced, the Promega luciferase
reporter assay was used. LARII was added to the lysate to measure the RLU for the
firefly luciferase while Stop&Glo was added to measure the Renilla luciferase. A
plate reader was used to measure the RLU or amount of light produced by each
construct and renilla. This was then used to calculate the ratio Renilla:Luciferase for
each SNP. Figure 3.6 shows the data produced by this assay for SNP 1666T>C.
To ensure accuracy at each stage of the protocol, several quality control tests
were used. Gel electrophoresis, DNA quantification, Colony PCR and DNA
sequencing and performing reactions in triplicate proved that each step was
successful before continuing to the next. The protocol for the luciferase reporter
construct design can be seen in Figure 3.5
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Figure 3.4 Primer Design for SNPs. Primers were designed to amplify regions of
~120 base pairs. (A) Shown here is the ideal design: one SNP located in the center
of the 120 basepairs. (B) Some SNPs were located too close to one another
therefore some designs required that one SNP was located in the primer for the SNP
of interest. Black lines represent the primer used for PCR amplification from the G
block. Stars represent SNP locations. Blue lines represent the overhangs added for
Gibson Assembly.
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Figure 3.5 CF Promoter SNP Reporter Assay Protocol. This pipeline outlines the
steps from (A) SNP isolation to (B) cloning and reporter assay. G blocks were
designed with 3000 basepairs of the CFTR promoter. Primers were designed to
amplify 120 basepairs of the G block. Gel electrophoresis was used to verify the
PCR product. Gibson Assembly was used to join the SNP sequence to the pGL4.23
plasmid. Plasmids were transfected into 16HBE cells and lysed to test the luciferase
expression differences in the reporter assay.
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Figure 3.6 RLU Data for SNP 1666T>C. Each reporter construct was transfected
and then incubated at 37°C for 2 days. After 2 days, the cells were lysed by PLB
and assayed using the Dual Reporter Luciferase Assay system. 100 ul LAR II and
100 ul Stop&Glo were added to the 20 ul of cell lysate. Data shown here are the
ratios of Luciferase:Renilla expression levels (multiplied by 100). SNP 1666T>C
significantly impacted luciferase gene expression (p>=0.01) (RLU, Relative
Luciferase Units).
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3.3 Analysis of SNPs Shown to Disrupt Reporter Expression
In order to explain the differences in luciferase gene expression, SNPs that
were observed to influence gene expression were then analyzed further. SNP
1666T>C was sourced from JLMS thesis; therefore this SNP contained a prediction
score for how it might affect gene expression. In James’ thesis, this SNP was
predicted to promote/ increase gene expression; however, the results of this study
show that SNP 1666T>C was observed to decrease gene expression in the luciferase
assay. To explain this difference in the machine learning score and observed gene
expression difference, DNA conservation and TF association were investigated
(Figure 3.7). SNP 1666T>C was not in an area of high conservation. SNP 1666T>C
was associated with 4 TFs in the reference sequence and 8 TFs in the experimental
sequence.
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Figure 3.7 DNA Conservation and TF Association Explain Luciferase Reporter
Assay Results. This figure illustrates the location of each SNP as a triangle (red CFTR2, blue - dbSNP, and green – JLMS thesis). The black arrow represents the
start codon of the CFTR gene. Each section represents 1000 base pairs. The graphs
show the RLU for the SNP 1666T>C. Blue bars represent the reference, while the
red bars represent the experimental SNP.
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CHAPTER FOUR

DISCUSSION

Overview
Cystic Fibrosis is an autosomal recessive disease that affects 1 in 3500
people in the United States. The disease is monogenic and is caused by mutations in
the CFTR gene. These mutations cause the CFTR protein to misfold which results
in a mutated CFTR protein. Therefore, CF patients cannot transport chloride (Cl-)
through their epithelial cells. Because of this reduced Cl- ion transport, mucus builds
up in the lungs and patients are more likely to develop lung infections. Patients also
experience issues in other areas such as GI tract, reproductive system, etc. Overall,
the CF disease has been well studied but there are several problems left to solve.
Current research on Cystic Fibrosis is primarily focused on DNA variants in
the CFTR gene and treatments for the DNA variants that are known to cause CF.
However, one of the most interesting problems with this disease is that two
individuals who have the same genotype for the CFTR gene can have very different
severities of the disease. Modifier genes, or genes that affect the disease but do not
cause the disease, are currently being studied as it is possible that other genes may
influence how CF presents in the body. However another less studied explanation is
that Promoter SNPs are causing the difference in CF severity. Because of this gap in
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knowledge, this thesis aims to look at the 3kb promoter region of the CFTR gene to
identify SNPs that disrupt gene expression.
Gene expression can be influenced by several factors such as: transcription
factors, enhancers and chromatin modifications. Transcription factors function by
binding to specific regions to recruit other factors to also bind there which results in
increased or decreased transcription. Chromatin modifications also influence gene
expression by modifying how easily the DNA can be accessed when it is compiled
around histones. Methylation and acetylation of DNA can also protect certain
regions from being transcribed. These modifications and regulatory factors are what
make the CFTR promoter a good candidate for explaining the differences in disease
severity.
To determine how CFTR promoter SNPs influence CFTR gene expression,
this project used a reporter assay. Reporter plasmids are often used to pair promoter
variants with a “reporter” gene (luciferase) to quantify the change in expression.
Often gene expression or protein expression is difficult to quantify; however, using
this method, quantification is simple. When luciferin is added to the luciferase
produced by the reporter plasmid, the amount of light produced indicates how much
protein was made. This can then be used to assume how the same SNP would
change CFTR expression in
epithelial cells.
The results of this experiment were accomplished by identifying and
isolating SNPs, designing luciferase reporter constructs and analyzing the data for
the SNPs shown to influence gene expression.
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4.1 Isolation of SNPs
There is currently research on specific Cystic Fibrosis DNA mutations in the
CFTR gene as well as other modifier regions that may affect how the disease works.
However, the gap in knowledge regarding Cystic Fibrosis lies within the promoter
region of the CFTR gene. The hypothesis for this thesis is based on this gap:
promoter mutations influence gene expression of CFTR and therefore the severity
of disease. Based on this hypothesis, the first step of this protocol was to identify
and isolate CFTR promoter mutations.
To begin to choose SNPs, DNA conservation was identified using the GERP
(Genomic Evolutionary Rate Profiling) track on UCSC Genome Browser. This
program compares DNA sequences from several different species such as mouse,
monkey, elephant, etc. GERP calculates conservation by using rejected substitution
(RS) rates (Expected substitution for neutral DNA - Observed substitution). These
RS values can be used to predict areas of high DNA conservation (Cooper et. al.,
2005).
If a region is shown to have high DNA conservation among multiple
species, this is indicative of a region that is important for gene regulation. By
identifying the regions of the CFTR promoter that have high DNA conservation, we
were able to predict areas that could affect gene expression.
To further choose SNPs in the CFTR promoter, transcription factor activity
was studied using ENCODE3, Factorbook and CisBP. ENCODE and Factorbook
provided data from Chip-seq experiments that showed regions of the promoter
where TFs were bound. ENCODE and Factorbook provided a more broad
understanding of where TF’s were bound to the promoter by using ChIP-Seq
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experiments. In order to further identify TF binding motifs, CisBP was used. This
program allows for shorter sequences to be entered and provides a list of TFs that
are different between the two sequences (Weiraunch et. al., 2014). In this case, the
reference and experimental sequences were used. Based on this, one could predict
how specific areas of the promoter affect gene expression. If the SNP normally
binds an activator TF, then the mutated reporter assay would be expected to have
decreased gene expression. This prediction can then be compared to the luciferase
expression later in the reporter assay.
The CFTR2 database provided a list of variants that were found in CF
patients and their family members (Table 3.2) The data from CFTR2 provides the
location, population and severity of the disease symptoms found in that patient or
family member.
This information allowed for a wide range of patient’s SNPs to be tested, which
helps to prove the hypothesis. Of the 19 from CFTR2, 11 were found in CF patients.
The SNPs from JLMS thesis include 6 that were predicted to promote gene
expression and 2 that disrupt gene expression (Table 3.1). These were collected by
using a DeltaSVM model to score DNA variants. To determine the score, known
regulatory sequences were used to train the system. The DeltaSVM was then able to
read random sequences to “score” the SNP based on whether it was more likely to
disrupt or promote gene expression. Based on this data, 8 SNPs were chosen for the
CFTR promoter. The 5 SNPs from dbSNP were selected as common SNPs in the
population which had minor allele frequencies of >= 0.1 (Table 3.3). This source
also provides a population that is most affected by the SNP.
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This source is important because these SNPs are more abundant in the population.
The chosen promoter SNPs are located in the regions 3000 basepairs
upstream of the start codon of CFTR. These SNPs have been found in Cystic
Fibrosis patients and/or family members, are common in the population or were
predicted to disrupt gene expression using DeltaSVM scores. Overall, 32 mutations
were identified from 3 sources (CFTR2, dbSNP and JLMS thesis). There are 19
SNPs from CFTR2, 5 from dbSNP and 8 from JLMS thesis, totalling 32 SNPs.
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4.2 Design of Luciferase Reporter Assays
The design of the luciferase reporter assay began with choosing how the
plasmid constructs would be created. There are several ways to do this: creating G
blocks of the promoter and then PCR amplification of each region or designing G
blocks of individual SNP regions. Site directed mutagenesis could also be used
along with the promoter G block to mutate individual SNPs. For this project, G
blocks were designed with the DNA sequence 3000 base pairs upstream of the start
codon. The reference G block contained the reference genome while the
experimental G block contained the reference genome with the mutations observed
from dbSNP, CFTR2 and JLMS thesis. The use of
these G blocks for this experiment was successful for all SNPs.
Primers were effective using 16-20 basepairs for PCR amplification and 1620 basepairs of overhang for Gibson Assembly. Initial reverse primers were
unsuccessful due to including an incorrect sequence for the Gibson Assembly
overhang. The overhang contained the reverse complement of the intended
sequence. This caused the PCR amplification step to work while the Gibson
Assembly step was unsuccessful. Once the primer was corrected, Gibson Assembly
was 75% successful overall and 59% successful for pairs of SNPs. Figure 3.4 shows
the final design for the primers. Figure “A” depicts the location of the SNP and the
primers that amplify that region of the G block. While
Figure “B” shows how this was modified for SNPs that were too close to one
another. In this case, nearby SNPs were included in the primer so that the only
difference between the reference and experimental was the SNP in question.
Because Gibson Assembly was unsuccessful in the first experiments using the
55

Gibson Assembly Master Mix, the second round of experiments were conducted
using Hifi Gibson Assembly Master Mix. This solution was created using a higher
fidelity polymerase for difficult to clone DNA sequences such as sequences that are
less than 120 basepairs or joining a larger number of fragments (NEB).
To determine how these SNPs would influence expression in epithelial cells,
a CF model that contained the same machinery for gene regulation was used. There
are several CF models to choose from: mice, pigs, ferrets, and several epithelial cell
lines (Keiser and Engelhardt, 2011). However, 16HBE cells (human bronchial
epithelial cells) were used because these cells highly express CFTR, contain the
same TFs that are associated with the SNPs, and are more easily maintained than
other CF models. This means that these cells can mimic a CF patient’s cells. These
cells also contain an SV40 plasmid that helps the cells express even more CFTR.
Transfecting these cells with the reporter plasmid, one can predict how the cells in
patients express CFTR.
To normalize the data, several controls were used. Renilla was used to
provide a baseline RLU for each of the reactions. The same concentration of renilla
and firefly luciferase was added to each of the SNP transfection reactions; therefore,
the ratio of Renilla:Luciferase gave a number that was normalized across all of the
reactions. This prevented one reaction having a higher RLU simply because it
contained more Luciferase constructs.
To ensure that each step was successful, several quality control tests were
implemented into the protocol. Quality control results showed bands of the expected
size using gel electrophoresis after PCR amplification, DNA quantification ensured
correct amounts of DNA after PCR amplification and PCR cleanup, colony PCR
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and gel electrophoresis after transformation showed bands of the correct size and
sequencing of plasmids showed the correct sequence after transformation and
isolation of DNA. All transfection and luciferase assays were performed in
triplicate. These quality control elements allowed for verification at each step in the
project.
Upon completion of this project, a pipeline was created to assay luciferase
expression of CFTR promoter SNPs in an epithelial cell line. Table 4.1 shows the
pipeline used from SNP collection to data analysis of the luciferase assay. This
pipeline can be used in future experiments on other gene promoters and/or in other
cell lines.
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Table 4.1 Promoter SNP Reporter Assay Pipeline. The pipeline from SNP
collection to Luciferase assay is shown here. The method is listed in the top column
while the description of each is listed in the second column.

58

4.3 Analysis of Promoter SNPs that Disrupted Gene Expression
After conducting the reporter assay and data analysis of the SNPs, SNP
1666T>C was observed to significantly influencing gene expression. The reference
allele produced a Renilla:Luciferase RLU of 8.25 while the experimental allele’s
RLU was 5.6 which means that the SNP decreased gene expression by 69.3%.
SNP 1666T>C was originally sourced from the JLMS data, so there was a
Delta SVM predicted score for how this SNP would affect gene expression. SNP
1666T>C was predicted to promote gene expression by the JLMS thesis; however,
in this experiment there was a decrease. The gene expression difference observed
can be explained by the DNA conservation and TF association data.
Conservation of the DNA sequence between species at specific regions is
often an indicator that this region could be important in gene expression. For SNP
1666T>C, one would expect that this SNP would be located in a region of high
DNA conservation due to the drastic decrease in gene expression. While this is not
the case, SNP 1666T>C is located near a region of high conservation and many
other SNPs in this project were located in areas of high conservation. Further
population studies showed that SNP 1666T>C has an allele frequency of 0.006371
and was observed in 1 African Male.
To further explain the observed decrease in gene expression for SNP
1666T>C, transcription factors associated with this SNP were studied more closely.
Transcription factors influence gene expression by binding to specific sequences
and recruiting other factors to bind to the DNA such as RNA polymerase. Figure
3.1 shows regions where TFs have been observed to bind based on Factorbook and
ENCODE data. Based on this data, SNP 1666T>C is associated with POLR2A and
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FOXA1. POLR2A (RNA Polymerase II Subunit A) is a transcriptional activator and
is a subunit of RNA polymerase that combines with other factors to complete the
DNA binding portion of the polymerase. FOXA1 (Forkhead box A1) is a
transcriptional activator in the liver which interacts with chromatin. CisBP data also
shows that the reference sequence is associated with 4 TF motifs, while the
experimental sequence is associated with 8 (Weiraunch et. al., 2014). Of these TFs,
3 could be eliminated based on RNAseq data from the Ann Harris lab showing that
these were not expressed in 16HBE cells (Stolzenburg et. al., 2016). Any TFs from
the CisBP data that had an RPKM (reads per kilobase per million mapped reads)
less than 1.0 were eliminated. The final TFs associated with the reference and
experimental TFs can be seen in Figure 4.1. Figure 4.1 shows the TFs associated
with the reference and experimental SNP and whether it is a transcriptional activator
or repressor. Figure 4.2 also lists the E-score (enrichment score) for each TF. An Escore greater than 0.45 is indicative of strong binding or DNA binding motif
sequence similarity. Therefore, all TFs listed have high sequence similarity;
however, JDP2 has the highest E score for the experimental SNP. This could
explain the gene expression difference seen in the reporter assay. The proposed
mechanism for how these TFs interact can be seen in Figure 4.2. JDP2 has the
highest binding motif sequence similarity for this SNP and is a transcriptional
repressor. JDP2 also represses the activity of the JUN TF that is also associated with
this SNP. Therefore, when JDP2 binds to the promoter, gene expression would be
expected to decrease (Jin et. al., 2002). This mechanism could explain the results we
see in the reporter assay.
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Based on these findings, the reference sequence would be expected to be
activating transcription while the experimental sequence would be expected to
disrupt both TFs from binding and therefore decrease transcription. This explains
the significant decrease in gene expression between the reference and experimental
SNP.
Because of the significant differences observed in the luciferase expression
between reference and experimental SNPs which can be explained with DNA
conservation and TF association, the hypothesis that promoter SNPs are influencing
gene expression and thus disease severity is further demonstrated.
To continue this project, the remaining 31 SNPs would need to be
transfected into the 16HBE cells and measured for luciferase activity. Once this was
completed, one would have a much better understanding of the CFTR promoter and
how gene regulation was changed with each of the SNPs. Using this data along with
the TF predictions from ENCODE, Factorbook and CisBP for each SNP, this would
produce a group of TFs that could be affecting gene regulation (Weiraunch et. al.,
2014). To see if these TFs are binding to the motifs in vivo, ChIP-seq could be used.
ChIP-seq cross links proteins with DNA to see what sequence the DNA is bound to.
For example, these specific SNP sequences could be crosslinked in the presence of
several TFs to see which are binding in these cells. If the same TFs bind in vivo as
predicted, this will verify the predictions and further explain the differences
observed in gene expression.
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Figure 4.1 Predicted TF Change for SNP 1666T>C. CisBP data showed that there
were 4 TFs associated with the reference SNP and 8 for the experimental SNP. The
E score also predicts which TF has the most sequence similarity for the TF binding
motif. This data can be used to interpret how gene expression changes between the
reference and experimental SNPs.
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Figure 4.2 Proposed Mechanism for Transcription Factor Binding at Position -1666. This
image shows how the TFs associated with this SNP may interact. Shown here, JDP2
binds more preferentially to the promoter and represses the other TFs. The JUN/FOS
complex which would activate transcription is not formed due to dimerization of JDP2
and JUN. This explains why the gene expression levels decrease in the experimental
SNP. Red, repressor; green, activator.
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4.4 Conclusions
CFTR DNA Promoter SNPs observed in Cystic Fibrosis patients and their
families as well as SNPs produced by machine learning show a change in gene
expression in relation to the reference genome. The pipeline created to assay these
was successful in the 16HBE cell type and can be used for other promoter SNPs and
other cell types. Promoter SNPs show significant expression differences between
the reference and experimental SNPs which could be due gene regulation factors.
Further research will need to be conducted to identify exactly how these SNPs are
influencing CFTR expression and whether or not these are the cause of the differing
severities seen in CF patients.
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